1Geus B， Hendriksen CFM． In vivoand in vitro production of monoclonal antibodies:current possibilities and futureperspectives[J]． Res Immunol， 1998， 149： 533．
2Nashan B， Moore R， Amlot P， et al． Randomised trial of basiliximab versusplacebo for control of acute cellular rejection in renal allograft recipients[J]． Lancet，1997， 350： 1 193．
3Kahan BD， Rajagopalan PR， Hall M． Reduction of the occurrence of acutecellular rejection among renal allograft recipients treated with basiliximab， a chimericanti－ interleukin－ 2 receptor monoclonal antibody[J]． Transplantation， 1999， 67：276．
4Nashan B， Light S， Hardie IR， et al． Reduction of acute renal allograftrejection by daclizumab:Daclizumab Double Therapy Study Group[J]． Transplantation，1999， 67： 110．
5Elliot MJ， Maini RN， Feldmann M， et al． Randomised double－ blindcomparison of chimeric monoclonal antibody to tumour necrosis factor a(cA2) versus placeboin rheumatoid arthritis[J]． Lancet， 1994， 344： 1 105．
6Maini RN， Breedveld FC， Kalden JR， et al． Therapeutic efficacy of multipleintravenous infusions of anti－ tumor necrosis factor a monoclonal anfibody combined withlow－ dose weekly methotrexate in rheumatoid arthritis[J]． Arthritis Rheum， 1998，41： 1 552．
7Maini RN， St Clair EW， Brccdvcld FC， et al． Infliximab(chimcric anti－tumour necrosis factor a monoclomal antibody)versus placebo in rheumatoid arthritispatients receiving concomitant methotrexate:a randomised phase Ⅲ trial[J]． Lancet，1999， 354： 1 932．
8Lipsky P， St Clair EW， Furst D， et al． 54－ week clinical and radiographicresults from the ATTRACT trial:a phase Ⅲ study of infliximab in patients with active RAdespite methotrexate[J]． Arthritis Rheum， 1999， 42： 401．
9Targan SR， Hanauer SB， van Deventer SJH， et al． A short term study ofchimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease[J]． N E-ng1 J Med， 1997， 337： 1 029．
10Present DH， Rutgeerts P， Targan S， et al． Infliximab for the treatment offistulas in patients with Crohn's disease[J]． N Engl J Med， 1999， 340： 1 398．
